Income statement
USD
Annual
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -11K | -22K | -264 | -317 | -317 |
| Operating Income | -5M | -10M | -4M | -2M | -3M |
| EBITDA | -5M | -10M | -3M | -2M | -3M |
| Net Income | -4M | -10M | -3M | -2M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RenovaCare, Inc. (RCAR) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +53.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +53.5%, free cash flow +4.2% with operating margin 0.0% and ROIC -224.7%. Stock Foundry combines RCAR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RCAR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RCAR Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RCAR and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$3.7M
-74.0% YoY
Free Cash Flow
-$1.7M
+17.4% YoY
Revenue Growth
+0.0%
EPS Growth
+53.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -11K | -22K | -264 | -317 | -317 |
| Operating Income | -5M | -10M | -4M | -2M | -3M |
| EBITDA | -5M | -10M | -3M | -2M | -3M |
| Net Income | -4M | -10M | -3M | -2M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 7M | 12M | 15M | 3M |
| Total Assets | 4M | 8M | 12M | 16M | 3M |
| Total Liabilities | 1M | 1M | 281K | 393K | 1M |
| Shareholder Equity | 2M | 7M | 12M | 15M | 2M |
| Total Debt | 30K | 80K | 0 | 0 | 1M |
| Net Debt | -3M | -7M | -12M | -15M | -2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+17.4% YoY
Capital Expenditures
0
Free Cash Flow
2M
+17.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-94.7%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.